Linde Morsink, MD, this year’s recipient of the Editorial Award for Clinical Research, previews her lecture on using post transplantation cyclophosphamide (PTCy) in combination with a short duration of immune suppression to improve outcomes in older patients diagnosed with myeloid malignancies.
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe…
Here is a look back on all the FDA happenings from the month of January 2025.
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
This issue includes important information on the committee’s initiatives for the upcoming year, including recording podcasts, organizing informal meetups at different society meetings, collaborating with…
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current…
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
